SMARCA4 and lung adenocarcinoma: ICIs, immune checkpoint inhibitors; LUAD, lung adenocarcinoma; NA, not available; NSCLC, non‐small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression‐free survival; PR, partial response; SCLC, small‐cell lung cancer; SMARCA4‐d, SMARCA4‐deficient; SMARCA4‐m, SMARCA4‐mutant.